AzTrials
AzTrials

Pulmonary Embolism (Diagnosis)TIDE-PENCT07560293

3D-EIT for Diagnosis and Monitoring of Pulmonary Embolism

An observational study of Pulmonary Embolism (Diagnosis) and Venous Thromboembolism (VTE), run by Beijing Tsinghua Chang Gung Hospital.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Official record

Search all trials

Trial summary

This prospective observational study aims to validate three-dimensional electrical impedance tomography (3D-EIT) as a non-invasive bedside tool for the diagnosis and longitudinal monitoring of pulmonary embolism (PE). The study will include a PE cohort and a control cohort without PE or venous thromboembolism (VTE). Read more about this study

Who is it for?
Ages 18 years and older
How many people
115 participants
Where
No sites listed yet
Study dates
1 May 2026to 1 May 2028
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Participants will be recruited from Beijing Tsinghua Changgung Hospital. The study population will include: (1) adult patients with a first episode of pulmonary embolism confirmed by CT pulmonary angiography, and (2) control participants without pulmonary embolism or deep vein thrombosis who are scheduled for saphenous vein radiofrequency ablation for varicose veins. Control participants will undergo screening to exclude venous thromboembolism before enrollment.

Who may be able to join

  • Age 18 years or older
  • Body mass index (BMI) less than 50 kg/m²
  • Able to provide written informed consent
  • first episode of pulmonary embolism confirmed by CT pulmonary angiography (CTPA), with or without CT venography (CTV)

Who cannot join

  • Previous diagnosis of pulmonary embolism
  • Pregnancy
  • Thoracic deformity or chest wall abnormality preventing proper placement of the EIT electrode belt
  • Contraindications to EIT use, including implantable cardioverter-defibrillator, pacemaker, implanted pumps, or chest wounds limiting electrode placement
  • Concurrent participation in another interventional clinical study Hemodynamic instability requiring emergency intervention that precludes completion of the EIT examination (PE cohort only)
  • Any other condition judged by the investigator to make the participant unsuitable for study participation

About this study

Official title: Prospective Validation of Three-Dimensional Electrical Impedance Tomography for the Diagnosis, Risk Stratification, and Longitudinal Monitoring of Pulmonary Embolism

This prospective observational study aims to validate three-dimensional electrical impedance tomography (3D-EIT) as a non-invasive bedside tool for the diagnosis and longitudinal monitoring of pulmonary embolism (PE). The study will include a PE cohort and a control cohort without PE or venous thromboembolism (VTE). Using algorithms that separate ventilation and perfusion signals, 3D-EIT-derived indices, including the Matching Index (MI), Dead Space Index (DI), and Shunt Index (SI), will be quantified. The diagnostic performance of MI and DI will be evaluated against computed tomography pulmonary angiography (CTPA), and their associations with PE severity, risk stratification, and treatment response will be explored. This study is expected to support the clinical translation of 3D-EIT as a radiation-free bedside functional imaging tool for PE management.

Read the detailed description

Pulmonary embolism (PE) is a major cause of morbidity and mortality. Computed tomography pulmonary angiography (CTPA) is the current reference standard for PE diagnosis, but it is limited by radiation exposure, contrast administration, and poor suitability for bedside or repeated dynamic assessment. Three-dimensional electrical impedance tomography (3D-EIT) is a non-invasive, radiation-free imaging technique that enables bedside evaluation of regional lung ventilation and perfusion.

The objective of this study is to validate the clinical utility of 3D-EIT for the diagnosis, risk stratification, and longitudinal monitoring of PE. The study will focus on EIT-derived ventilation-perfusion parameters, including the Matching Index (MI), Dead Space Index (DI), and Shunt Index (SI).

This is a prospective, single-center, observational case-control study conducted at Beijing Tsinghua Changgung Hospital. Two cohorts will be enrolled:

  1. A control cohort without PE or VTE, recruited from patients scheduled for saphenous vein radiofrequency ablation for varicose veins who meet predefined screening criteria.
  2. A PE cohort including patients with a first episode of PE confirmed by CTPA. Participants in the control cohort will undergo one 3D-EIT examination to establish reference ranges for MI, DI, and SI. Participants in the PE cohort will undergo 3D-EIT within 24 hours after diagnostic CTPA. Repeated EIT examinations will be performed after thrombolytic therapy when applicable, at hospital discharge, and at 1-month follow-up to evaluate dynamic changes over time.

The primary objective is to assess the diagnostic performance of MI and DI for identifying PE using CTPA as the reference standard. Secondary objectives include evaluating the association of EIT-derived indices with PE severity, CTPA-based obstruction burden, risk stratification category, and temporal changes following treatment.

Statistical analyses will include estimation of reference ranges in the control cohort, receiver operating characteristic (ROC) analysis for diagnostic performance, correlation analyses between EIT and CTPA-derived parameters, and longitudinal analyses of repeated EIT measurements in the PE cohort.

Keywords
Pulmonary Embolism, Electrical Impedance Tomography, Three-dimensional Imaging, Lung Perfusion, Ventilation-Perfusion Mismatch
Medical subject headings
Pulmonary Embolism, Disease, Venous Thromboembolism

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Diagnostic Accuracy of EIT-derived Dead Space Index (DI) for Pulmonary Embolism

    Sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) of the Dead Space Index (DI) measured by 3D-EIT for diagnosing pulmonary embolism, using CT pulmonary angiography (CTPA) as the reference standard.

    Measured: Baseline (within 24 hours after CTPA for the PE cohort and at enrollment for the control cohort)

Secondary outcomes (1)
  1. Diagnostic Accuracy of EIT-derived Matching Index (MI) for Pulmonary Embolism

    Sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) of the Matching Index (MI) measured by 3D-EIT for diagnosing pulmonary embolism, using CT pulmonary angiography (CTPA) as the reference standard.

    Measured: Baseline (within 24 hours after CTPA for the PE cohort and at enrollment for the control cohort)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 May 2026
  2. Study start1 May 2026 (estimated)
  3. Primary completion1 May 2028 (estimated)
  4. Study completion1 May 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
115 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07560293
Sponsor's protocol ID
3D-EIT for PE
Acronym
TIDE-PE
Status last verified
Apr 2026
First submitted
24 Apr 2026
Last updated
1 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in